INTRODUCTION
Current status of robotic surgery in Japan first introduced in the Keio University Hospital for clinical studies in March 2000 [1] . Thereafter, it was intro duced in the Kyushu University Hospital. The ZEUS robotic surgical system (Computer Motion Inc, Santa Barbara, CA, USA) was also introduced in a few insti tu tions including the Kyushu University Hospital. These robotic systems were used in the field of general digestive sur gery, thoracic surgery, and urology as clinical studies and were evaluated by the MHLW. But neither system had been approved for a medical device and the Zeus sur gi cal system was withdrawn from the market.
The da Vinci S, the nextgeneration surgical system, was introduced for RALP as a clinical study in Tokyo Medical Hospital in 2006 and was approved as a medical device in Japan in November 2009. The fields of indication are as follows: general digestive surgery, thoracic surgery (excluding cardiac surgery), urology, and gynecology. Concerning approval, the MHLW established the following guidelines:
(1) Compliance with "the Guidelines for Endoscopic Surgery (established on August 29, 1992 )" established by the Japan Society for Endoscopic Surgery (JSES).
(2) Compliance with "the perspectives on new medical devices" announced by JSES.
(3) Regarding institutions, physicians, and medical teams: constant records of endoscopic surgery in gastro enterological surgery, thoracic surgery, urology, and gyne cology (presence of a JSES boardcertified surgeon).
(4) The presence of a medical team with knowledge of the performance and use of the device.
(5) Physicians and medical teams conducting surgery must participate in training programs provided by the company and have obtained certification. The validity of the program content must be evaluated and reviewed by JSES.
(6) Infrastructure allowing for procedures (e.g., thora cotomy, laparotomy) to be performed in emergencies.
AVENUES FOR THE APPROVAL FOR HEALTH INSURANCE COVERAGE
There are two paths for the approval of individual medical technologies for health insurance coverage. One route involves the submission of a request by a relevant scientific society to the Medical Technology Evaluation Subcommittee. The review results are sent to the Central Social Insurance Medical Council. The second route involves a proposal from a medical institution sent to the Advanced Medical Treatment Expert Meeting. If a medical technology is approved as an advanced medical treatment, an associated medical cost other than the advanced medical treatment is covered by public health insurance. The mixed billing of the advanced medical fee and the health insured fee is exceptionally permitted by MHLW. Data are accumulated as advanced medical treatment data, and the results of the evaluation for health insurance coverage are sent to the Central Social Insurance Medical Council. Reimbursement prices for the devices themselves are not determined for expensive medical devices; instead, they are evaluated on the basis of newly defined technical fees. The costeffectiveness of medical devices, particularly surgeryassisting robots, is evaluated by the Central Social Insurance Medical Council. If the price of a device remains high without higher efficacy, it may be rejected from he alth insurance coverage for Japanese citizens. In this ca se, the comparison target will be laparoscopic surgery. The verification of not only the inferiority but also the supe riority of shortterm (e.g., suture failure, complication) and longterm (e.g., survival) outcomes immediately af ter surgery compared to control operations is required. Meanwhile, although reductions in burden and fatigue on surgeons should also be considered as increased efficacy in evaluations, this point is unfortunately not debated much.
ACCREDITATION SYSTEM
For laparoscopic surgery, the JSES and the JSE have established the board certification system for physicians [2] . However, the system is not mandatory for medical care that is covered by health insurance. No board certification system exists for either society for robotic surgery, and thus certification must be obtained from Intuitive Surgical Inc.
The guideline for da Vinciassisted surgery for uro lo gi cal disease was established in April 2010 by the Japanese Uro lo gi cal Association and the JSE and was revised on November 30, 2012. The recommendations in this guideline include star ting robotic surgery ideally with radical prostatectomy, ex perience with 10 or more patients undergoing robotic sur gery, including observation and instructorsupervised surgery, and approval from the institutional ethics committees for each operative pro cedure besides radical prostatectomy. In addi tion, it is re commended that a boardcertified surgeon skilled in uro logical laparoscopic techniques participate or provide instruc tion at the beginning of renal or adrenal gland sur gery. However, in radical prostatectomy, there is no reference to the participation of or instruction from a boardcertified surgeon skilled in urological laparoscopic technique. Therefore, it is possible for institutions to alter nate between open radical prostatectomy and RALP. JSES announced a similar recommendation in July 2011 (http:// www.jses.or.jp/member/pdf_regulation/robot_20120815.pdf).
In November 2014, the first proctor training session was held at the 28th Congress of JSE. The roles of proctors are to (1) introduce safe and smooth robotic surgery, and (2) provide feedback to the JSE regarding any probl ems experienced. This proctor system is scheduled to be implemented starting in 2015 and is likely to be proactively used in institutions introducing roboticassisted laparoscopic partial nephrectomy (RALPN) and robotic assisted laparoscopic radical cystectomy (RALRC).
ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
In Japan, surgeries to treat localized prostate cancer include retropubic radical prostatectomy (RRP), perineal radical prostatectomy (PRP), minimumincision endoscopic radical prostatectomy (MIERP), laparoscopic radical prostatectomy (LRP), and RALP.
RRP has been the standard therapy used to achieve longterm cancer control, as well as preserve urinary and sexual functional. RRP has the advantage of being an extraperitoneal procedure with the use of tactile sensation. Importantly, RRP also provides a good open surgery tra ining opportunity for young surgeons. However, the draw backs of this procedure include a long skin incision and the risk of blood loss, which have led urological surgeons to opt for less invasive surgery.
Although PRP has the advantages of less blood loss [3] and postoperative pain [4] compared to RRP, this procedure has been used in a limited number of institutions in Japan because pelvic lymph node dissection cannot be performed simultaneously through the same approach.
LRP was first reported by Schuessler in 1997 [5] . Aft er reports of the improved outcome of patients under going this surgery by Guillonneau et al. [68] , LRP was introduced in Japanese clinical practice in 1999. After evaluating the ef f icacy and safety of LRP performed at accredited institutions, this procedure was approved for health insurance coverage by the MHLW in 2006. Surgeons and institutions must be accredited to perform LRP. Thus far, LRP has not been widely accepted in Japan because of the technical difficulties involved in the handling of the pelvis, such as during bladder neck incision, neurovascular bundle preservation, prostatic apex incision, and urethra and bladder neck anastomosis.
MIERP was first performed by Kihara et al. [9] and was approved by the MHLW in 2006 as an advanced medical treatment; this procedure has been covered by public health insurance since 2008. Surgeons and their institutions must be accredited to perform MIERP. The procedure has been widely applied as a minimally invasive surgery [10] , and 77 institutions were accredited in 2011. The characteristics of this procedure include a minimal incision of around 5 cm in length, an extraperitoneal approach, and a magnified view using endoscopy. Because the incision length can be adjusted according to the intraoperative condition, surgeons skilled in RRP can sa fely perform MIERP. Although spe cial retractors are needed, neither carbon dioxide nor a cannula port is required. Therefore, MIERP is economical compared with LRP or RALP. Despite this, MIERP has not been widely adopted because of the technical difficulty in the execution of the procedure through a small incision.
RALP was introduced in 2006 [11] . Tokyo Medical Uni versity applied for RALP to be considered an advan ced me di cal treatment and the MHLW approved the treat ment in 2008. Without a large prospective comparative stu dy after 3year usage, the public health insurance pro gram began to cover the cost of RALP in April 2012. Since then, the number of RALP procedures performed has been increasing rapidly (Fig. 1) .
The da Vinci surgical system has allowed more free and delicate movement of forceps and scissors than other procedures under a threedimensional view. On the other hand, there are disadvantages to the procedure; for example, there is no tactile sensation, there is an added risk of steep Trendelenburg position, and the cost is higher.
Initial concerns about RALP in Japan were its safety and efficacy. Surgeons should be aware of the possibility of traction or pressure injury due to the loss of tactile sen sation, particularly in early cases. The difference in posi ti ve surgical margins between RALP and LRP at the site of surgery was reported by Nagoya City University [12] ; exce ssive countertraction to the posterior prostate might cause capsular cleavage, leading to posterior positive surgical margins. Because the Trendelenburg position significantly inc reases cerebral and intraocular pressure, neurological or vision complications are a concern, particularly in patients with intracranial disease or glaucoma. In patients without preexisting ocular disease, shortterm steep Trendelenburg positioning during the procedures appears to pose little or no increase in the risk of intraocular pressure [13] . A neuroocular benefit has been reported from the use of a modified Trendelenburg position [14] .
The perioperative outcomes of RALP during its initial year were recently reported by Sugihara et al. [15] . In this report, RALP was compared with other types of radical prostatectomy by using the Japanese Diagnosis Procedure Combination database (April 2012-March 2013), including 7,202 RRP/PRP (55.4%), 2,483 LRP (19.1%), 1,181 MIERP (9.1%), and 2,126 RALP (16.4%) cases. Even in its initial year, RALP was associated with a significantly lower co mplication rate (0.8% overall) despite the long anesthesia time and high cost. The anesthesia time during RALP was 42.6%, 6.9%, and 23.9% more than that during RRP/PRP, LRP, and MIERP, respectively. The total cost of RALP was 52.4%, 13.2%, and 22.8% higher than that of RRP/ PRP, LRP, and MIERP, respectively. The cost differences are mainly due to the official fee for the surgery itself, which is approximately 4,108 United States dollar (USD), 7,743 USD, 5,978 USD, and 9,528 USD f or RRP/PRP, LRP, MIERP, and RALP, respectively (These costs were calculated at the currency rate of 100 Japanese Yen=1 USD in April 2012).
ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY
Partial nephrectomy is widely accepted as a standard therapy for localized renal tumors. Surgical approaches such as open laparoscopyassisted minimum incision have been chosen according to institutional mastership. Laparo scopic partial nephrectomy (LPN) has been performed in Japan since the 1990s, and by 2013, LPN was performed in 1,149 cases according to the results of the 12th JSES sur vey. However, advanced skills are required for the pre cise resection and suturing involved in the procedure within a limited ischemic time. Furthermore, laparoscopic pro cedures are challenging, and their difficulty depends on the location of the tumor, such as the renal sinus. In this regard, RALPN is very attractive for its free motion under a threedimensional view. In 2013, 119 renal tumors were treated with RALPN according to the results of the 12th JSES survey (Fig. 2) . Kobe University applied for RALPN to be considered an advanced medical treatment and it was approved by the MHLW in June 2014.
Multiinstitutional clinical trials have only started to prove the clear benefits of RALPN over LPN. The pri mary endpoints of this procedure are renal function and cancer control. The goals of the rates of negative surgical margin and the ischemic time (≤25 minutes) are >98% and >40%, respectively. The clinical data of 1354 LPN cases from 54 Japanese institutions were used as a historical con trol [16] . This is a singlearm openlabel trial for 100 patients with renal cell carcinoma (cT1N0M0) (http:// www.mhlw.go.jp/file/05Shingikai12401000Hokenkyoku Soumuka/0000053764.pdf ). If this trial is able to prove the clinical benefits of RALPN, the procedure will sub sequently be covered by public health insurance in Japan.
OTHER TYPES OF ROBOTIC SURGERY FOR UROLOGICAL DISEASES
Other types of robotic surgery for urological disease have also been performed as clinical trials in a limited number of institutions in Japan. These include RALRC and robotassisted laparoscopic pyeloplasty (RALPP). The acceptable outcomes of RALRC were reported from Tokyo Medical University [17] . There were several presentations on the preliminary results of RALRC and RALPP for a small number of patients at the 28th Congress of JSE. These presentations mainly addressed the issues of feasi bility and safety. These robotic procedures will also be submitted for approval as an advanced medical treatment.
ROBOTIC-ASSISTED SURGERY FOR GASTRIC CANCER
Laparoscopic surgery for gastric cancer is an emerging minimally invasive surgery. Japan demonstrated a 10fold increase in the use of laparoscopic surgery between 1991 and 2009 [18] , accounting for 42% of laparoscopic operations for stages I and II gastric cancer in 2010 [18] . Laparoscopic distal and total gastrectomies were performed in 7,341 and 1,103 patients, respectively, in 2009 [18] . Despite the large num bers of cases performed, conclusive evidence on the longterm oncologic safety of laparoscopic gastric surgery is still pending for early gastric cancer and is certainly lacking for advanced gastric cancer [19, 20] . The Japanese Gastric Cancer Association defined standard gastrectomy as resection of not less than twothirds of the stomach with a D2 lymph node dissection with extended dissection aro und the stomach and upper border of the pancreas [21] . Be cause laparoscopic gastrectomy requires advanced sur gi cal skills, the robotic advantages are believed to ease the learning curve [22] and also to improve surgical out comes [23] . Fujita Health University applied for roboticassisted gastrectomy to be considered an advanced medical treat ment and this was approved by the MHLW in July 2014. A multiinstitutional clinical trial has begun to prove the safety, clinical efficacy, and costeffectiveness of the procedure. The trial is a singlearm openlabel trial for 330 patients with stages I and II gastric cancer. The primary endpoint is postoperative complications corresponding to ClavienDindo classification [2426] greater than grade III. The goal is for a complication rate of less than 6.4%. The complication rate among 801 laparoscopic gastrectomy cases from Fujita Health University, Kyoto University, and Saga University are being used as a historical con trol (http://www.mhlw.go.jp/f ile/05Shingikai12401000 HokenkyokuSoumuka/0000056538.pdf ). The verification of superiority of roboticassisted laparoscopic gastrectomy in this trial will be required for public health insurance coverage for this procedure.
ROBOTIC-ASSISTED SURGERY FOR RECTAL CANCER
Laparoscopic surgery is widely performed for rectal cancer in Japan. However, the open conversion rate is relatively high and longterm results remain a critical con cern for this procedure [27] . The ability to carry out total mesorectal excision laparoscopically requires in tensive training [28] . Roboticassisted rectal surgery is attracting attention as an approach to overcome the limi tations in intrapelvic operations in conventional lapa roscopic surgery. However, no evidence of superiority over laparoscopic surgery has yet been found [2831] . It has been reported that disadvantages in the early period after robot introduction include longer operation time and interference with forceps and arms [2831] . Recently, the shortterm outcomes for 113 cases including advanced rectal cancer were reported from Shizuoka Cancer Center Hospital. That report showed low morbidity and a low conversion rate, even for cases requiring complicated, robotassisted, lateral lymph node dissection [32] .
ROBOTIC-ASSISTED SURGERY FOR GYNECOLOGICAL DISEASE
Laparoscopic surgery is a technique generally perform ed for treating benign gynecological diseases. Regarding malignant diseases, laparoscopic hysterectomy for endo met rial cancer has recently been approved for health in su rance coverage.
Similarly, robotic surgery is considered highly useful in lymphadenectomy and uterine cancer surgery, which require delicate surgical operations in a deep narrow area of the pelvic cavity [33] .
In Japan, the first roboticassisted laparoscopic radical hysterectomy (RALH) was performed in March 2009 at Tokyo Medical University; a total of 261 patients have undergone robotic surgery since then. Among them, 127 patients had malignant disease. When classified by operative procedure, RALH plus pelvic lymph node di ssection were performed in 86 patients, RALH in 16, extended RALH in 15, and roboticassisted laparoscopic semiradical hysterectomy in 10. Although one patient (0.4%) switched to laparotomy and two received allogeneic blood transfusions, no patient experienced serious complications, such as postoperative bleeding or vaginal stump dehiscence [34] .
Preliminary results of RALH from several institutions were presented at the 27th annual meeting of the JSES in 2014. Although requiring a long operative time, RALH plus paraaortic or pelvic lymph node dissection was performed safely and effectively without serious complications. There have been specific issues in the gynecological field; for example, laparoscopic surgery for infertility has mainly de veloped, and the number of radical hysterectomies has de creased.
TRANSORAL ROBOTIC SURGERY
Transoral robotic surgery (TORS) has been reported as an otolaryngology clinical application [35, 36] . In TORS, a threedimensional endoscope and two arms of the robot are inserted through the mouth cavity to extract tumors in cases of middle or lower pharyngeal and larynx cancer. This procedure has not been widely adopted in Japan to date, because its use in the f ield of otolaryngology is not yet approved. In 2014, Tokyo Medical University, Kyoto University, and Tottori University jointly started a multicenter TORS clinical trial as a science research promotion project through the MHLW. A clinical trial is being conducted with 20 patients treated with TORS as advanced medical treatment, which is scheduled to be submitted for marketing approval.
ROBOTIC-ASSISTED SURGERY FOR THYROID DISEASE
Roboticassisted thyroid surgery has been reported in a clinical study conducted in 2014 patients at four Korean institutions [37] , as well as in Europe [38] . In all of these studies, this procedure exhibited superiority and resulted in comparable or fewer complications compared with the conventional method. In Japan, this procedure has been performed for a small number of patients in Tokyo Me dical University and Kanazawa Medical University alone.
Although roboticassisted thyroid surgery using the da Vinci system has proven useful and safe in many clinical studies [37, 38] , its costbenefit balance is being debated in the United States [39] .
ROBOTIC-ASSISTED THORACIC SURGERY
Longterm clinical outcomes f rom roboticassisted thymectomy and lobectomy have recently been reported from Germany and the United States [4042] . In Japan, outstanding operability under threedimensional vision, a characteristic of roboticassisted surgery, is considered usef ul f or mediastinal disease, and the possibility of its superiority over thoracoscopic surgery is a current subject of controversy. Thymus disease of the anterior mediastinum is found in a narrow region with a major blood vessel nearby, making thoracoscopic surgery diffi cult in some cases. Roboticassisted surgery, which can be suf f iciently performed with a lateral approach, is considered useful for thymectomy, thymoma, and myas thenia gravis requiring elaborate surgery. The advantages of roboticassisted surgery include its use in treating tumors at the top of the chest, tumors near the diaphragm in the posterior mediastinum, or esophageal tumors that require suturing.
Furthermore, preoperative simulation and intra opera tive navigation using the SYNAPSE VINCENT (Fujifilm Corp., Tokyo, Japan) for robotassisted thoracic surgery (RATS) have been reported to enable efficient planning of the operation settings, allowing the tumor location and depicting surrounding tissues to be detected quickly, accu rately, and safely [43] . However, due to the cost of RATS, this technique has not been widely adopted. It is reported that at least 300 RATS cases per year at one institution are required to prevent a deficit in income under the Ja panese Health Insurance System [44] . The judges of the Advanced Medical Treatment Expert Meeting requested that RATS be verified for higher costbenefit performance compared to the conventional videoassisted thoracic sur gery.
ROBOTIC-ASSISTED SURGERY FOR ESOPHAGEAL CANCER
In curative surgery for thoracic esophageal cancer, it is important to thoroughly dissect the upper mediastinal lymph node centered around the recurrent laryngeal nerve. The major issues of this procedure are recurrent laryngeal nerve palsy and associated postoperative laryngopharynx functional impairment. An endoscopic surgeryassisting robot has several characteristics that address the issues of conventional thoracoscopic surgery, including a clear enlarged view with a threedimensional monitor, as well as joint, motion scaling, and blurring prevention functions. A reduced incidence of recurrent laryngeal nerve palsy with the use of a robotic system was reported in a study from Fujita Health University [45] .
Recently, transhiatal robotic manipulation has also been reported. In this approach, the middle mediastinal lymph node is dissected by use of a robotic approach after performing upper mediastinal lymph dissection through a cervical incision. Thus, radical esophagectomy together with threefield lymphadenectomy can be completed with out any transthoracic procedure [46] . 
CONCLUSIONS
Currently, more than 180 institutions have installed the da Vinci surgical system in Japan. The most com monly performed procedure is RALP because of the limi tations of health insurance coverage. Roboticassisted partial nephrectomy and roboticassisted gastrectomy have recently begun as advanced medical treatment to be evaluated for health insurance coverage. Other types of robotic surgery have been performed as clinical trials. The verification of superiority of outcome and costbenefit balance over conventional laparoscopic surgery will be required. Despite the potential advantages of robotic use, robotic surgery will have a tough road to be utilized for a wide range of surgical treatments without a downward price revision of the robotic equipment.
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